Literature DB >> 3606629

Action of calcium antagonists on multidrug resistant cells. Specific cytotoxicity independent of increased cancer drug accumulation.

D F Cano-Gauci, J R Riordan.   

Abstract

Previous studies have shown that calcium channel blockers can overcome, at least partially, multidrug resistance (MDR). This study was undertaken to attempt to determine the mechanisms whereby these agents bring about this effect. Their influence on the uptake and retention of several cancer drugs and on the toxic actions of these compounds was assessed employing MDR cell lines from several species. The wild-type drug sensitive parent cells proved to be more susceptible than the multidrug resistant variants to the effects of calcium channel blockers on cancer drug accumulation. This was shown for verapamil, nifedipine and the calmodulin inhibitor trifluoperazine acting on human, mouse and Chinese hamster ovary (CHO) cell lines. The enhancement of drug accumulation by calcium antagonists was similar to that caused by non-ionic detergents. Furthermore, verapamil was unable to alter 45Ca2+ accumulation in sensitive or resistant cells, suggesting that these agents act in a calcium-independent manner. Verapamil accumulation in multidrug resistant cells was reduced compared to sensitive cells. In spite of this reduced accumulation, however, verapamil alone was much more toxic to multidrug resistant cells than to the sensitive cells. This suggests that calcium channel blockers are specifically toxic to MDR cells by virtue of an interaction with the MDR cell surface distinct from that involved in promoting cellular accumulation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3606629     DOI: 10.1016/0006-2952(87)90139-0

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  26 in total

1.  Verapamil sensitisation to alkaloids on colchicine-selected human colon adenocarcinoma cells.

Authors:  M J Ruiz Gómez; A Souviron; L Gil; M Martínez Morillo
Journal:  J Physiol Biochem       Date:  2001-12       Impact factor: 4.158

Review 2.  Collateral sensitivity as a strategy against cancer multidrug resistance.

Authors:  Kristen M Pluchino; Matthew D Hall; Andrew S Goldsborough; Richard Callaghan; Michael M Gottesman
Journal:  Drug Resist Updat       Date:  2012-04-06       Impact factor: 18.500

Review 3.  Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.

Authors:  Chung-Pu Wu; Anna Maria Calcagno; Suresh V Ambudkar
Journal:  Curr Mol Pharmacol       Date:  2008-06       Impact factor: 3.339

Review 4.  Genetic basis of multidrug resistance of tumor cells.

Authors:  S E Kane; I Pastan; M M Gottesman
Journal:  J Bioenerg Biomembr       Date:  1990-08       Impact factor: 2.945

5.  Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil.

Authors:  A R Safa
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

Review 6.  Using purified P-glycoprotein to understand multidrug resistance.

Authors:  A B Shapiro; V Ling
Journal:  J Bioenerg Biomembr       Date:  1995-02       Impact factor: 2.945

7.  Expression of verapamil hypersensitivity in multidrug-resistant cells grown as multicellular spheroids.

Authors:  M Anderson; J R Warr
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

8.  Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody.

Authors:  E B Mechetner; I B Roninson
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

Review 9.  Is resistance useless? Multidrug resistance and collateral sensitivity.

Authors:  Matthew D Hall; Misty D Handley; Michael M Gottesman
Journal:  Trends Pharmacol Sci       Date:  2009-09-15       Impact factor: 14.819

10.  Non-glucocorticoid steroid analogues (21-aminosteroids) sensitize multidrug resistant cells to vinblastine.

Authors:  I Abraham; C L Wolf; K E Sampson
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.